Boston Scientific Corporation (NYSE: BSX) announces positive clinical data from the Research in Severe Asthma (RISA) Trial, demonstrating the long-term safety of bronchial thermoplasty (BT) in patients treated with the Company’s AlairTM Bronchial Thermoplasty System. Follow-up data demonstrate that stable lung function is maintained and late clinical complications are absent over a five-year period in patients with severe refractory asthma treated with BT. Results were presented today at the annual European Respiratory Society (ERS) Congress in Amsterdam by Michel Laviolette, M.D., Professor of Medicine, Institut universitaire de cardiologie et de pneumologie at Université Laval in Québec City, Canada.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/bostonscientific/52128/
